Modality
ADC
MOA
BTKi
Target
VEGF
Pathway
JAK/STAT
CKD
Development Pipeline
Preclinical
~Jun 2020
→ ~Sep 2021
Phase 1
~Dec 2021
→ ~Mar 2023
Phase 2
Jun 2023
→ Jun 2027
Phase 2Current
NCT03068775
2,297 pts·CKD
2023-06→2027-06·Active
2,297 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-06-211.2y awayPh3 Readout· CKD
Trial Timeline
Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
P2/3
Active
Catalysts
Ph3 Readout
2027-06-21 · 1.2y away
CKD
Active|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03068775 | Phase 2/3 | CKD | Active | 2297 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Zanuderotide | Novartis | Phase 1/2 | VEGF | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 | |
| TAK-8730 | Takeda | Phase 2 | VEGF | |
| TAK-2403 | Takeda | Phase 2 | WEE1 | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| GIL-2011 | Gilead Sciences | Preclinical | VEGF |